bs-0591R [Primary Antibody]
DR4 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: DR4

Immunogen Range: 401-468/468


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 8797

Swiss Prot: O00220

Source: KLH conjugated synthetic peptide derived from human DR4

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)

Predicted Molecular Weight: 48


Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Furui Han. et al. In vivo and in vitro study on hepatotoxicity of Tris-(2, 3-dibromopropyl) isocyanurate exposure via mitochondrial and death receptor pathway. ECOTOX ENVIRON SAFE. 2022 Nov;246:114186Read more>>
  • Zhao Zhang. et al. Effect of matrine in MAC-T cells and their transcriptome analysis: A basic study. PLOS ONE. 2023 Jan;18(1):e0280905Read more>>
VALIDATION IMAGES

MCF-7 lysates probed with DR4 Polyclonal Antibody, Unconjugated (bs-0558R) at 1:500 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.


Lane 1: Human Jurkat cell lysates; Lane 2: Human A549 cell lysates; Lane 3: Human HUVEC cell lysates; Lane 4: Human HeLa cell lysates probed with TNFRSF10A Polyclonal Antibody, Unconjugated (bs-0591R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.